扫码登录小狗阅读
-
THEM6介导的脂质代谢重编程促使前列腺癌治疗耐药
THEM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer
From：Embo Mol Med Date：2022-03-07
IF：12.1 类型：基础
Read：177 Author：Arnaud Blomme
-
派姆单抗治疗微卫星不稳定性患者——高度晚期子宫内膜癌：来自KEYNOTE-158研究的结果
Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
From：J Clin Oncol Date：2022-03-01
IF：44.5 类型：临床
Read：94 Author：O'Malley DM
-
KHDRBS3促进结直肠癌的多药耐药和非锚定生长
KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer
From：Cancer Sci Date：2022-03-01
IF：6.7 类型：基础
Read：253 Author：Ukai S
-
DOT1L是治疗三阴性乳腺癌的新型肿瘤干细胞靶点
DOT1L is a novel cancer stem cell target for triple negative breast cancer
From：Clin Cancer Res Date：2022-02-08
IF：12.5 类型：基础
Read：99 Author：Hetakshi Kurani
-
工程化CAR-T细胞原位激活小分子药物
Engineering CAR-T cells to activate small-molecule drugs in situ
From：Nat Chem Biol Date：2022-02-05
IF：15.0 类型：基础
Read：227 Author：Thomas J. Gardner
-
胰腺癌肿瘤细胞与基质细胞的相互作用增强肿瘤细胞氧化还原状态的氧化性
Interactions with stromal cells promote a more oxidized cancer cell redox state in pancreatic tumors
From：Sci Adv Date：2022-01-21
IF：14.1 类型：基础
Read：103 Author：Datta R
-
应用IRAK1/4抑制剂清除慢性髓系白血病干细胞
Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors
From：Nat Commun Date：2022-01-12
IF：14.9 类型：基础
Read：145 Author：Tanaka Y
-
GATA4调控的分泌程序通过募集细胞毒性CD8 T细胞发挥肿瘤抑制作用
A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells
From：Nat Commun Date：2022-01-11
IF：14.9 类型：基础
Read：189 Author：Patel RS
-
Axicabtagene ciloleucel治疗复发或难治性惰性非霍奇金淋巴瘤(ZUMA-5)：一项单臂、多中心、2期试验
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
From：Lancet Oncol Date：2022-01-01
IF：41.3 类型：临床
Read：180 Author：Jacobson CA
-
工程菌通过肿瘤间质重塑增强免疫治疗和靶向治疗的疗效
Engineered Bacteria Enhance Immunotherapy and Targeted Therapy through Stromal Remodeling of Tumors
From：Adv Healthc Mater Date：2022-01-01
IF：7.4 类型：基础
Read：131 Author：Thomas SC
-
使用多组学机器学习预测乳腺癌治疗反应
Multi-omic machine learning predictor of breast cancer therapy response
From：Nature Date：2022-01-01
IF：49.9 类型：基础
Read：166 Author：Sammut SJ
-
纳武单抗-伊匹单抗联用巩固疗法与观察组中放化疗后局限性小细胞肺癌的疗效对比--随机II期ETOP/IFCT 4-12 STIMULI试验结果
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy --results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
From：Ann Oncol Date：2022-01-01
IF：32.9 类型：临床
Read：141 Author：Peters S
-
在癌症免疫治疗中，纳米颗粒递送重组IL-2(BALLkine-2)可持续抑制肿瘤且全身性不良反应较少
Nanoparticle delivery of recombinant IL-2 (BALLkine-2) achieves durable tumor control with less systemic adverse effects in cancer immunotherapy
From：Biomaterials Date：2022-01-01
IF：12.4 类型：基础
Read：54 Author：Kim J
-
CD40刺激作为分子佐剂用于癌症疫苗和其他免疫治疗
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
From：Cell Mol Immunol Date：2022-01-01
IF：11.5 类型：综述
Read：149 Author：Bullock TNJ
-
完全切除的非小细胞肺癌患者术后放疗与无术后放疗的对比研究：一项开放标签、随机、3期试验
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial
From：Lancet Oncol Date：2022-01-01
IF：41.3 类型：临床
Read：340 Author：Le Pechoux C
-
卡非佐米-地塞米松二联与达拉木单抗-卡非佐米-地塞米松三联疗法治疗复发性或难治性多发性骨髓瘤患者的疗效比较（CANDOR）：一项随机、多中心、开放标签的3期研究的最新结果
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
From：Lancet Oncol Date：2022-01-01
IF：41.3 类型：临床
Read：136 Author：Usmani SZ
-
达拉非尼联合曲美替尼治疗BRAFV600E突变型低级别和高级别胶质瘤（ROAR）：一项多中心、开放标签、单臂、2期、篮式试验
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
From：Lancet Oncol Date：2022-01-01
IF：41.3 类型：临床
Read：77 Author：Wen PY
-
40岁之前确诊的年轻多发性骨髓瘤患者的流行病学概况：来自法国的经验
EPIDEMIOLOGICAL LANDSCAPE OF YOUNG MULTIPLE MYELOMA PATIENTS DIAGNOSED EARLIER THAN 40 YEARS: THE FRENCH EXPERIENCE
From：Blood Date：2021-12-23
IF：22.1 类型：临床
Read：242 Author：Caulier A
-
微生物群特异性T滤泡辅助细胞驱动三级淋巴结构和针对结直肠癌的抗肿瘤免疫
Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer
From：Immunity Date：2021-12-14
IF：31.7 类型：基础
Read：185 Author：Abigail E. Overacre-Delgoffe
-
177Lu Dotatate联合长效奥曲肽与大剂量长效奥曲肽治疗中肠神经内分泌肿瘤的疗效比较（NETTER-1）：一项开放标签、随机、对照、3期试验的最终总生存率和长期安全性结果
177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
From：Lancet Oncol Date：2021-12-01
IF：41.3 类型：临床
Read：85 Author：Strosberg JR
